Drug intelligence / Profile preview

autologous CAR-T (Hebei Senlang Biotechnology)

Development stage: Unknown
Lead developer: Senlang Bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

Autologous CAR-T (Hebei Senlang Biotechnology) refers to a portfolio of investigational autologous chimeric antigen receptor (CAR) T-cell therapies developed by Hebei Senlang Biotechnology for the treatment of B-cell malignancies, including leukemia and lymphoma. The lead candidate, SENL-001, targets the CD19 antigen, while other candidates such as SENL-101 and SENL-201 utilize dual-targeting strategies (CD19/CD22 and CD19/CD20, respectively) to mitigate antigen escape. The therapy involves collecting a patient's T cells via leukapheresis, genetically engineering them ex vivo to express a CAR specific to tumor-associated antigens, and re-infusing the modified cells following lymphodepleting chemotherapy (typically cyclophosphamide and fludarabine). These therapies are primarily being evaluated in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL).

Other names: Auto CAR-Tautologous CD19-targeted CAR-T cells (Hebei Senlang)autologous CD19/CD22-targeted CAR-T cells (Hebei Senlang)

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on autologous CAR-T (Hebei Senlang Biotechnology).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous CAR-T (Hebei Senlang Biotechnology).